Clinical trial results for
previously treated colorectal
cancer (MSI-H/dMMR)
For adults and children 12 years of age and older whose MSI‑H/dMMR colorectal cancer (CRC) has spread to other parts of the body (metastatic) and who have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working
Actor portrayals.
OPDIVO + YERVOY is not approved
for people younger than 12 years of age.
In a clinical trial, the overall response rate to OPDIVO + YERVOY was looked at in 119 people with MSI-H/dMMR CRC that had spread to other parts of the body and were treated with at least one line of therapy that included fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy.
Of these people, 82 people received prior treatment with all three of the following: fluoropyrimidine, oxaliplatin, and irinotecan.
Tumors disappeared completely (complete response)
Tumors shrank
(partial response)
Tumors shrank or disappeared completely (overall response)
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
OPDIVO + YERVOY will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults and children 12 years of age and older whose MSI-H/dMMR CRC has spread to other parts of the body (metastatic) and who have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO in combination with YERVOY was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
